

Docket No.: PH114205.00/KMZR215101.00400
Customer No. 27160

AF/1642#
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

YEATMAN et al.

Application Serial No. 09/444,711 : Group Art Unit: 1642

Filed: November 24, 1999

: Examiner: Alana M. Harris

For: MUTATED SRC ONCOGENE COMPOSITION AND METHOD

TRANSMITTAL LETTER

Commissioner for Patents
Washington, D.C. 20231

RECEIVED
APR 01 2002
TECH CENTER 1600/2900

Dear Sir:

Submitted herewith are the following documents for filing in the above-referenced application:

1. Response to final Office Action dated January 2, 2002 and Amendment;
2. Notice of Appeal and Authorization to charge \$160 filing fee to Deposit Account No. 50-1710; and
3. Return postcard.

Please charge any shortage in fees due in connection with the filing of this communication, or credit any overpayment to Deposit Account No. 50-1710.

Respectfully submitted,

Gilberto M. Villacorta, Ph.D.
Registration No. 34,038

Gianna Julian-Arnold
Registration No. 36,358

Patent Administrator
KATTEN MUCHIN ZAVIS ROSENMAN
525 West Monroe Street, Suite 1600
Chicago, IL 60661-3963
Fax: (312) 906-1021

Date: 3/28/02
DC:4125998v1-114205.400/215101.00400

Docket No. PH114205.400/KMZR215101.00400
Customer No. 27160

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Yeatman et al.

Serial No.: 09/444,711

Filed: 11/24/1999

For: MUTATED SRC ONCOGENE COMPOSITION AND METHODS



Examiner: A. Harris

Art Unit: 1642

RECEIVED

APR 01 2002

TECH CENTER 1600/2900

AMENDMENT

Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Dear Sir:

This is in response to the communication mailed January 2, 2002, having a three month shortened statutory period of response set to expire April 2, 2002. The following remarks and amendments are respectfully submitted. A Notice of Appeal with appropriate fees is being filed concurrently herewith.

In the Claims:

Please enter the following amended claims:

B¹ 29. (Amended) An isolated polynucleotide encoding a mutant c-Src protein, wherein the polynucleotide has a codon 531, and wherein the codon 531 is a stop codon.

B² 35. (Amended) An oligonucleotide capable of recognizing and distinguishing a mutant c-Src gene having a codon 531, wherein the codon 531 is a stop codon from a wild-type c-Src gene.

REMARKS

Claims 1-28 were originally pending in the subject application. Claims 1-28 were cancelled without prejudice or disclaimer, and new claims 29-38 were added. Claims 29 and 35 are amended in the instant response to more particularly point out and distinctly claim the subject matter, which Applicants regard as their invention. Therefore, the claims now under consideration are claims 29-38, as amended. These amended claims are supported by the